603520
vs
S
Shanghai Composite
603520
Over the past 12 months, Zhejiang Starry Pharmaceutical Co Ltd has underperformed Shanghai Composite, delivering a return of +22% compared to the Shanghai Composite's +22% growth.
Stocks Performance
603520 vs Shanghai Composite
Performance Gap
603520 vs Shanghai Composite
Performance By Year
603520 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Zhejiang Starry Pharmaceutical Co Ltd
Glance View
Zhejiang Starry Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of active ingredient and intermediate X-CT non-ionic contrast agent and fluoroquinolones series. The company is headquartered in Taizhou, Zhejiang and currently employs 1,818 full-time employees. The company went IPO on 2016-03-09. The X-ray contrast medium's major product is iohexol active pharmaceutical ingredient. Quinolone antimicrobial agents' major products are levofloxacin hydrochloride active pharmaceutical ingredient and levofloxacin hemihydrates active pharmaceutical ingredient.
